<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.1//EN" "http://www.w3.org/TR/xhtml11/DTD/xhtml11.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
<title>Bibliography</title>
</head>
<body>
<div class="csl-bib-body" style="line-height: 1.35; ">
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[1]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">B. Xu and R. A. Ghossein, “Advances in Thyroid Pathology: High Grade Follicular Cell-derived Thyroid Carcinoma and Anaplastic Thyroid Carcinoma,” <i>Adv Anat Pathol</i>, vol. 30, no. 1, pp. 3–10, Jan. 2023, doi: <a href="https://doi.org/10.1097/PAP.0000000000000380">10.1097/PAP.0000000000000380</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1097%2FPAP.0000000000000380&amp;rft_id=info%3Apmid%2F36306188&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Advances%20in%20Thyroid%20Pathology%3A%20High%20Grade%20Follicular%20Cell-derived%20Thyroid%20Carcinoma%20and%20Anaplastic%20Thyroid%20Carcinoma&amp;rft.jtitle=Advances%20in%20Anatomic%20Pathology&amp;rft.stitle=Adv%20Anat%20Pathol&amp;rft.volume=30&amp;rft.issue=1&amp;rft.aufirst=Bin&amp;rft.aulast=Xu&amp;rft.au=Bin%20Xu&amp;rft.au=Ronald%20A.%20Ghossein&amp;rft.date=2023-01-01&amp;rft.pages=3-10&amp;rft.spage=3&amp;rft.epage=10&amp;rft.issn=1533-4031&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[2]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">E. J. Sherman <i>et al.</i>, “Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial,” <i>The Lancet Oncology</i>, vol. 24, no. 2, pp. 175–186, Feb. 2023, doi: <a href="https://doi.org/10.1016/S1470-2045(22)00763-X">10.1016/S1470-2045(22)00763-X</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1016%2FS1470-2045(22)00763-X&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Radiotherapy%20and%20paclitaxel%20plus%20pazopanib%20or%20placebo%20in%20anaplastic%20thyroid%20cancer%20(NRG%2FRTOG%200912)%3A%20a%20randomised%2C%20double-blind%2C%20placebo-controlled%2C%20multicentre%2C%20phase%202%20trial&amp;rft.jtitle=The%20Lancet%20Oncology&amp;rft.stitle=The%20Lancet%20Oncology&amp;rft.volume=24&amp;rft.issue=2&amp;rft.aufirst=Eric%20J&amp;rft.aulast=Sherman&amp;rft.au=Eric%20J%20Sherman&amp;rft.au=Jonathan%20Harris&amp;rft.au=Keith%20C%20Bible&amp;rft.au=Ping%20Xia&amp;rft.au=Ronald%20A%20Ghossein&amp;rft.au=Christine%20H%20Chung&amp;rft.au=Nadeem%20Riaz&amp;rft.au=G%20Brandon%20Gunn&amp;rft.au=Robert%20L%20Foote&amp;rft.au=Sue%20S%20Yom&amp;rft.au=Stuart%20J%20Wong&amp;rft.au=Shlomo%20A%20Koyfman&amp;rft.au=Michael%20F%20Dzeda&amp;rft.au=David%20A%20Clump&amp;rft.au=Saad%20A%20Khan&amp;rft.au=Manisha%20H%20Shah&amp;rft.au=Kevin%20Redmond&amp;rft.au=Pedro%20A%20Torres-Saavedra&amp;rft.au=Quynh-Thu%20Le&amp;rft.au=Nancy%20Y%20Lee&amp;rft.date=2023-02&amp;rft.pages=175-186&amp;rft.spage=175&amp;rft.epage=186&amp;rft.issn=14702045&amp;rft.language=en"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[3]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">E. Maurer <i>et al.</i>, “Mutation-based, short-term ‘neoadjuvant’ treatment allows resectability in stage IVB and C anaplastic thyroid cancer,” <i>Eur Arch Otorhinolaryngol</i>, Jan. 2023, doi: <a href="https://doi.org/10.1007/s00405-023-07827-y">10.1007/s00405-023-07827-y</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1007%2Fs00405-023-07827-y&amp;rft_id=info%3Apmid%2F36637521&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Mutation-based%2C%20short-term%20%22neoadjuvant%22%20treatment%20allows%20resectability%20in%20stage%20IVB%20and%20C%20anaplastic%20thyroid%20cancer&amp;rft.jtitle=European%20archives%20of%20oto-rhino-laryngology%3A%20official%20journal%20of%20the%20European%20Federation%20of%20Oto-Rhino-Laryngological%20Societies%20(EUFOS)%3A%20affiliated%20with%20the%20German%20Society%20for%20Oto-Rhino-Laryngology%20-%20Head%20and%20Neck%20Surgery&amp;rft.stitle=Eur%20Arch%20Otorhinolaryngol&amp;rft.aufirst=Elisabeth&amp;rft.aulast=Maurer&amp;rft.au=Elisabeth%20Maurer&amp;rft.au=F.%20Eilsberger&amp;rft.au=S.%20W%C3%A4chter&amp;rft.au=J.%20Riera%20Knorrenschild&amp;rft.au=A.%20Pehl&amp;rft.au=K.%20Holzer&amp;rft.au=A.%20Neubauer&amp;rft.au=M.%20Luster&amp;rft.au=D.%20K.%20Bartsch&amp;rft.date=2023-01-13&amp;rft.issn=1434-4726&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[4]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">C. Lorimer <i>et al.</i>, “Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres,” <i>Clin Oncol (R Coll Radiol)</i>, vol. 35, no. 1, pp. e60–e66, Jan. 2023, doi: <a href="https://doi.org/10.1016/j.clon.2022.10.017">10.1016/j.clon.2022.10.017</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1016%2Fj.clon.2022.10.017&amp;rft_id=info%3Apmid%2F36379836&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Dabrafenib%20and%20Trametinib%20Therapy%20for%20Advanced%20Anaplastic%20Thyroid%20Cancer%20-%20Real-World%20Outcomes%20From%20UK%20Centres&amp;rft.jtitle=Clinical%20Oncology%20(Royal%20College%20of%20Radiologists%20(Great%20Britain))&amp;rft.stitle=Clin%20Oncol%20(R%20Coll%20Radiol)&amp;rft.volume=35&amp;rft.issue=1&amp;rft.aufirst=C.&amp;rft.aulast=Lorimer&amp;rft.au=C.%20Lorimer&amp;rft.au=L.%20Cheng&amp;rft.au=R.%20Chandler&amp;rft.au=K.%20Garcez&amp;rft.au=V.%20Gill&amp;rft.au=K.%20Graham&amp;rft.au=W.%20Grant&amp;rft.au=S.%20Sardo%20Infirri&amp;rft.au=J.%20Wadsley&amp;rft.au=L.%20Wall&amp;rft.au=N.%20Webber&amp;rft.au=K.%20H.%20Wong&amp;rft.au=K.%20Newbold&amp;rft.date=2023-01&amp;rft.pages=e60-e66&amp;rft.spage=e60&amp;rft.epage=e66&amp;rft.issn=1433-2981&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[5]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">C. Jungels, J. M. Pita, and G. Costante, “Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy,” <i>Curr Opin Oncol</i>, vol. 35, no. 1, pp. 1–9, Jan. 2023, doi: <a href="https://doi.org/10.1097/CCO.0000000000000918">10.1097/CCO.0000000000000918</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1097%2FCCO.0000000000000918&amp;rft_id=info%3Apmid%2F36398690&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Anaplastic%20thyroid%20carcinoma%3A%20advances%20in%20molecular%20profiling%20and%20targeted%20therapy&amp;rft.jtitle=Current%20Opinion%20in%20Oncology&amp;rft.stitle=Curr%20Opin%20Oncol&amp;rft.volume=35&amp;rft.issue=1&amp;rft.aufirst=Christiane&amp;rft.aulast=Jungels&amp;rft.au=Christiane%20Jungels&amp;rft.au=Jaime%20Miguel%20Pita&amp;rft.au=Giuseppe%20Costante&amp;rft.date=2023-01-01&amp;rft.pages=1-9&amp;rft.spage=1&amp;rft.epage=9&amp;rft.issn=1531-703X&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[6]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">J. Yuan and Y. Guo, “Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management,” <i>Cancers (Basel)</i>, vol. 15, no. 1, p. 179, Dec. 2022, doi: <a href="https://doi.org/10.3390/cancers15010179">10.3390/cancers15010179</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.3390%2Fcancers15010179&amp;rft_id=info%3Apmid%2F36612173&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Targeted%20Therapy%20for%20Anaplastic%20Thyroid%20Carcinoma%3A%20Advances%20and%20Management&amp;rft.jtitle=Cancers&amp;rft.stitle=Cancers%20(Basel)&amp;rft.volume=15&amp;rft.issue=1&amp;rft.aufirst=Jiaqian&amp;rft.aulast=Yuan&amp;rft.au=Jiaqian%20Yuan&amp;rft.au=Yong%20Guo&amp;rft.date=2022-12-28&amp;rft.pages=179&amp;rft.issn=2072-6694&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[7]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">V. Subbiah <i>et al.</i>, “Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study,” <i>Ann Oncol</i>, vol. 33, no. 4, pp. 406–415, Apr. 2022, doi: <a href="https://doi.org/10.1016/j.annonc.2021.12.014">10.1016/j.annonc.2021.12.014</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1016%2Fj.annonc.2021.12.014&amp;rft_id=info%3Apmid%2F35026411&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Dabrafenib%20plus%20trametinib%20in%20patients%20with%20BRAF%20V600E-mutant%20anaplastic%20thyroid%20cancer%3A%20updated%20analysis%20from%20the%20phase%20II%20ROAR%20basket%20study&amp;rft.jtitle=Annals%20of%20Oncology%3A%20Official%20Journal%20of%20the%20European%20Society%20for%20Medical%20Oncology&amp;rft.stitle=Ann%20Oncol&amp;rft.volume=33&amp;rft.issue=4&amp;rft.aufirst=V.&amp;rft.aulast=Subbiah&amp;rft.au=V.%20Subbiah&amp;rft.au=R.%20J.%20Kreitman&amp;rft.au=Z.%20A.%20Wainberg&amp;rft.au=J.%20Y.%20Cho&amp;rft.au=J.%20H.%20M.%20Schellens&amp;rft.au=J.%20C.%20Soria&amp;rft.au=P.%20Y.%20Wen&amp;rft.au=C.%20C.%20Zielinski&amp;rft.au=M.%20E.%20Cabanillas&amp;rft.au=A.%20Boran&amp;rft.au=P.%20Ilankumaran&amp;rft.au=P.%20Burgess&amp;rft.au=T.%20Romero%20Salas&amp;rft.au=B.%20Keam&amp;rft.date=2022-04&amp;rft.pages=406-415&amp;rft.spage=406&amp;rft.epage=415&amp;rft.issn=1569-8041&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[8]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">F. Ragusa <i>et al.</i>, “Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer,” <i>Int J Mol Sci</i>, vol. 23, no. 10, p. 5731, May 2022, doi: <a href="https://doi.org/10.3390/ijms23105731">10.3390/ijms23105731</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.3390%2Fijms23105731&amp;rft_id=info%3Apmid%2F35628540&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Combination%20Strategies%20Involving%20Immune%20Checkpoint%20Inhibitors%20and%20Tyrosine%20Kinase%20or%20BRAF%20Inhibitors%20in%20Aggressive%20Thyroid%20Cancer&amp;rft.jtitle=International%20Journal%20of%20Molecular%20Sciences&amp;rft.stitle=Int%20J%20Mol%20Sci&amp;rft.volume=23&amp;rft.issue=10&amp;rft.aufirst=Francesca&amp;rft.aulast=Ragusa&amp;rft.au=Francesca%20Ragusa&amp;rft.au=Silvia%20Martina%20Ferrari&amp;rft.au=Giusy%20Elia&amp;rft.au=Sabrina%20Rosaria%20Paparo&amp;rft.au=Eugenia%20Balestri&amp;rft.au=Chiara%20Botrini&amp;rft.au=Armando%20Patrizio&amp;rft.au=Valeria%20Mazzi&amp;rft.au=Giovanni%20Guglielmi&amp;rft.au=Rudy%20Foddis&amp;rft.au=Claudio%20Spinelli&amp;rft.au=Salvatore%20Ulisse&amp;rft.au=Alessandro%20Antonelli&amp;rft.au=Poupak%20Fallahi&amp;rft.date=2022-05-20&amp;rft.pages=5731&amp;rft.issn=1422-0067&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[9]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">Y. Luo <i>et al.</i>, “Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma,” <i>Front Endocrinol (Lausanne)</i>, vol. 13, p. 859013, 2022, doi: <a href="https://doi.org/10.3389/fendo.2022.859013">10.3389/fendo.2022.859013</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.3389%2Ffendo.2022.859013&amp;rft_id=info%3Apmid%2F35574031&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Immune%20Checkpoint%20Protein%20Expression%20Defines%20the%20Prognosis%20of%20Advanced%20Thyroid%20Carcinoma&amp;rft.jtitle=Frontiers%20in%20Endocrinology&amp;rft.stitle=Front%20Endocrinol%20(Lausanne)&amp;rft.volume=13&amp;rft.aufirst=Yi&amp;rft.aulast=Luo&amp;rft.au=Yi%20Luo&amp;rft.au=Yi-Chen%20Yang&amp;rft.au=Cen-Kai%20Shen&amp;rft.au=Ben%20Ma&amp;rft.au=Wei-Bo%20Xu&amp;rft.au=Qi-Feng%20Wang&amp;rft.au=Yan%20Zhang&amp;rft.au=Tian%20Liao&amp;rft.au=Wen-Jun%20Wei&amp;rft.au=Yu%20Wang&amp;rft.date=2022&amp;rft.pages=859013&amp;rft.issn=1664-2392&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[10]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">J.-S. Lee <i>et al.</i>, “Prognosis of Anaplastic Thyroid Cancer with Distant Metastasis,” <i>Cancers (Basel)</i>, vol. 14, no. 23, p. 5784, Nov. 2022, doi: <a href="https://doi.org/10.3390/cancers14235784">10.3390/cancers14235784</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.3390%2Fcancers14235784&amp;rft_id=info%3Apmid%2F36497268&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Prognosis%20of%20Anaplastic%20Thyroid%20Cancer%20with%20Distant%20Metastasis&amp;rft.jtitle=Cancers&amp;rft.stitle=Cancers%20(Basel)&amp;rft.volume=14&amp;rft.issue=23&amp;rft.aufirst=Jin-Seok&amp;rft.aulast=Lee&amp;rft.au=Jin-Seok%20Lee&amp;rft.au=Jun%20Sung%20Lee&amp;rft.au=Hyeok%20Jun%20Yun&amp;rft.au=Hojin%20Chang&amp;rft.au=Seok%20Mo%20Kim&amp;rft.au=Yong%20Sang%20Lee&amp;rft.au=Hang-Seok%20Chang&amp;rft.au=Cheong%20Soo%20Park&amp;rft.date=2022-11-24&amp;rft.pages=5784&amp;rft.issn=2072-6694&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[11]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">A. Jannin <i>et al.</i>, “Anaplastic Thyroid Carcinoma: An Update,” <i>Cancers (Basel)</i>, vol. 14, no. 4, p. 1061, Feb. 2022, doi: <a href="https://doi.org/10.3390/cancers14041061">10.3390/cancers14041061</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.3390%2Fcancers14041061&amp;rft_id=info%3Apmid%2F35205809&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Anaplastic%20Thyroid%20Carcinoma%3A%20An%20Update&amp;rft.jtitle=Cancers&amp;rft.stitle=Cancers%20(Basel)&amp;rft.volume=14&amp;rft.issue=4&amp;rft.aufirst=Arnaud&amp;rft.aulast=Jannin&amp;rft.au=Arnaud%20Jannin&amp;rft.au=Alexandre%20Escande&amp;rft.au=Abir%20Al%20Ghuzlan&amp;rft.au=Pierre%20Blanchard&amp;rft.au=Dana%20Hartl&amp;rft.au=Benjamin%20Chevalier&amp;rft.au=Fr%C3%A9d%C3%A9ric%20Deschamps&amp;rft.au=Livia%20Lamartina&amp;rft.au=Ludovic%20Lacroix&amp;rft.au=Corinne%20Dupuy&amp;rft.au=Eric%20Baudin&amp;rft.au=Christine%20Do%20Cao&amp;rft.au=Julien%20Hadoux&amp;rft.date=2022-02-19&amp;rft.pages=1061&amp;rft.issn=2072-6694&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[12]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">D. Huang, J. Zhang, X. Zheng, and M. Gao, “Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis,” <i>Front Endocrinol (Lausanne)</i>, vol. 13, p. 920857, 2022, doi: <a href="https://doi.org/10.3389/fendo.2022.920857">10.3389/fendo.2022.920857</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.3389%2Ffendo.2022.920857&amp;rft_id=info%3Apmid%2F35846304&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Efficacy%20and%20Safety%20of%20Lenvatinib%20in%20Anaplastic%20Thyroid%20Carcinoma%3A%20A%20Meta-Analysis&amp;rft.jtitle=Frontiers%20in%20Endocrinology&amp;rft.stitle=Front%20Endocrinol%20(Lausanne)&amp;rft.volume=13&amp;rft.aufirst=Dongmei&amp;rft.aulast=Huang&amp;rft.au=Dongmei%20Huang&amp;rft.au=Jinming%20Zhang&amp;rft.au=Xiangqian%20Zheng&amp;rft.au=Ming%20Gao&amp;rft.date=2022&amp;rft.pages=920857&amp;rft.issn=1664-2392&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[13]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">W. Dong <i>et al.</i>, “Conditional Survival Rate Estimates for Anaplastic Thyroid Cancer Beyond the First Year: An Analysis of SEER Data (2004 to 2019),” <i>Thyroid</i>, Nov. 2022, doi: <a href="https://doi.org/10.1089/thy.2022.0339">10.1089/thy.2022.0339</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1089%2Fthy.2022.0339&amp;rft_id=info%3Apmid%2F36329668&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Conditional%20Survival%20Rate%20Estimates%20for%20Anaplastic%20Thyroid%20Cancer%20Beyond%20the%20First%20Year%3A%20An%20Analysis%20of%20SEER%20Data%20(2004%20to%202019)&amp;rft.jtitle=Thyroid%3A%20Official%20Journal%20of%20the%20American%20Thyroid%20Association&amp;rft.stitle=Thyroid&amp;rft.aufirst=Wenwu&amp;rft.aulast=Dong&amp;rft.au=Wenwu%20Dong&amp;rft.au=Takahiro%20Okamoto&amp;rft.au=Xiaoyu%20Ji&amp;rft.au=Jingzhe%20Xiang&amp;rft.au=Dalin%20Zhang&amp;rft.au=Ping%20Zhang&amp;rft.au=Hao%20Zhang&amp;rft.date=2022-11-03&amp;rft.issn=1557-9077&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[14]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">Y. H. Chen <i>et al.</i>, “Prior thyroid and non-thyroid cancer history do not significantly alter overall survival in patients diagnosed with anaplastic thyroid carcinoma,” <i>Thyroid</i>, Dec. 2022, doi: <a href="https://doi.org/10.1089/thy.2022.0350">10.1089/thy.2022.0350</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1089%2Fthy.2022.0350&amp;rft_id=info%3Apmid%2F36511380&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Prior%20thyroid%20and%20non-thyroid%20cancer%20history%20do%20not%20significantly%20alter%20overall%20survival%20in%20patients%20diagnosed%20with%20anaplastic%20thyroid%20carcinoma&amp;rft.jtitle=Thyroid%3A%20Official%20Journal%20of%20the%20American%20Thyroid%20Association&amp;rft.stitle=Thyroid&amp;rft.aufirst=Yu%20Han&amp;rft.aulast=Chen&amp;rft.au=Yu%20Han%20Chen&amp;rft.au=Maria%20Cabanillas&amp;rft.au=Jared%20Sperling&amp;rft.au=Li%20Xu&amp;rft.au=Maitrayee%20Goswami&amp;rft.au=Anastasios%20Maniakas&amp;rft.au=Michelle%20D.%20Williams&amp;rft.au=Stephen%20Y.%20Lai&amp;rft.au=Naifa%20Busaidy&amp;rft.au=Ramona%20Dadu&amp;rft.au=Mark%20E.%20Zafereo&amp;rft.au=Jennifer%20Rui%20Wang&amp;rft.date=2022-12-13&amp;rft.issn=1557-9077&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[15]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">J. Xiang, Z. Wang, W. Sun, and H. Zhang, “A relook at the 8th edition of the AJCC TNM staging system of anaplastic thyroid carcinoma: A SEER-based study,” <i>Clin Endocrinol (Oxf)</i>, vol. 94, no. 4, pp. 700–710, Apr. 2021, doi: <a href="https://doi.org/10.1111/cen.14371">10.1111/cen.14371</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1111%2Fcen.14371&amp;rft_id=info%3Apmid%2F33368530&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=A%20relook%20at%20the%208th%20edition%20of%20the%20AJCC%20TNM%20staging%20system%20of%20anaplastic%20thyroid%20carcinoma%3A%20A%20SEER-based%20study&amp;rft.jtitle=Clinical%20Endocrinology&amp;rft.stitle=Clin%20Endocrinol%20(Oxf)&amp;rft.volume=94&amp;rft.issue=4&amp;rft.aufirst=Jingzhe&amp;rft.aulast=Xiang&amp;rft.au=Jingzhe%20Xiang&amp;rft.au=Zhihong%20Wang&amp;rft.au=Wei%20Sun&amp;rft.au=Hao%20Zhang&amp;rft.date=2021-04&amp;rft.pages=700-710&amp;rft.spage=700&amp;rft.epage=710&amp;rft.issn=1365-2265&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[16]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">H. Zhang, Y.-C. Zhao, Q. Wu, L. Wang, and S. Sun, “The prognostic value of lymph node metastasis and the eighth edition of AJCC for patients with anaplastic thyroid cancer,” <i>Clin Endocrinol (Oxf)</i>, vol. 95, no. 3, pp. 498–507, Sep. 2021, doi: <a href="https://doi.org/10.1111/cen.14482">10.1111/cen.14482</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1111%2Fcen.14482&amp;rft_id=info%3Apmid%2F33864292&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The%20prognostic%20value%20of%20lymph%20node%20metastasis%20and%20the%20eighth%20edition%20of%20AJCC%20for%20patients%20with%20anaplastic%20thyroid%20cancer&amp;rft.jtitle=Clinical%20Endocrinology&amp;rft.stitle=Clin%20Endocrinol%20(Oxf)&amp;rft.volume=95&amp;rft.issue=3&amp;rft.aufirst=Hanpu&amp;rft.aulast=Zhang&amp;rft.au=Hanpu%20Zhang&amp;rft.au=Yan-Ci%20Zhao&amp;rft.au=Qi%20Wu&amp;rft.au=Lijun%20Wang&amp;rft.au=Shengrong%20Sun&amp;rft.date=2021-09&amp;rft.pages=498-507&amp;rft.spage=498&amp;rft.epage=507&amp;rft.issn=1365-2265&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[17]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">M. L. Rocha, K. W. Schmid, and P. Czapiewski, “The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma - systematic review and discussion of current therapeutic options,” <i>Contemp Oncol (Pozn)</i>, vol. 25, no. 3, pp. 213–223, 2021, doi: <a href="https://doi.org/10.5114/wo.2021.110052">10.5114/wo.2021.110052</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.5114%2Fwo.2021.110052&amp;rft_id=info%3Apmid%2F34729042&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The%20prevalence%20of%20DNA%20microsatellite%20instability%20in%20anaplastic%20thyroid%20carcinoma%20-%20systematic%20review%20and%20discussion%20of%20current%20therapeutic%20options&amp;rft.jtitle=Contemporary%20Oncology%20(Poznan%2C%20Poland)&amp;rft.stitle=Contemp%20Oncol%20(Pozn)&amp;rft.volume=25&amp;rft.issue=3&amp;rft.aufirst=Maria%20Linda&amp;rft.aulast=Rocha&amp;rft.au=Maria%20Linda%20Rocha&amp;rft.au=Kurt%20Werner%20Schmid&amp;rft.au=Piotr%20Czapiewski&amp;rft.date=2021&amp;rft.pages=213-223&amp;rft.spage=213&amp;rft.epage=223&amp;rft.issn=1428-2526&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[18]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">H. J. Kim, H.-S. Chang, and Y. H. Ryu, “Prognostic Role of Pre-Treatment [18F]FDG PET/CT in Patients with Anaplastic Thyroid Cancer,” <i>Cancers (Basel)</i>, vol. 13, no. 16, p. 4228, Aug. 2021, doi: <a href="https://doi.org/10.3390/cancers13164228">10.3390/cancers13164228</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.3390%2Fcancers13164228&amp;rft_id=info%3Apmid%2F34439382&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Prognostic%20Role%20of%20Pre-Treatment%20%5B18F%5DFDG%20PET%2FCT%20in%20Patients%20with%20Anaplastic%20Thyroid%20Cancer&amp;rft.jtitle=Cancers&amp;rft.stitle=Cancers%20(Basel)&amp;rft.volume=13&amp;rft.issue=16&amp;rft.aufirst=Hyun%20Jeong&amp;rft.aulast=Kim&amp;rft.au=Hyun%20Jeong%20Kim&amp;rft.au=Hang-Seok%20Chang&amp;rft.au=Young%20Hoon%20Ryu&amp;rft.date=2021-08-23&amp;rft.pages=4228&amp;rft.issn=2072-6694&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[19]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">I. Abe and A. K.-Y. Lam, “Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging,” <i>Histol Histopathol</i>, vol. 36, no. 3, pp. 239–248, Mar. 2021, doi: <a href="https://doi.org/10.14670/HH-18-277">10.14670/HH-18-277</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.14670%2FHH-18-277&amp;rft_id=info%3Apmid%2F33170501&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Anaplastic%20thyroid%20carcinoma%3A%20Updates%20on%20WHO%20classification%2C%20clinicopathological%20features%20and%20staging&amp;rft.jtitle=Histology%20and%20Histopathology&amp;rft.stitle=Histol%20Histopathol&amp;rft.volume=36&amp;rft.issue=3&amp;rft.aufirst=Ichiro&amp;rft.aulast=Abe&amp;rft.au=Ichiro%20Abe&amp;rft.au=Alfred%20King-Yin%20Lam&amp;rft.date=2021-03&amp;rft.pages=239-248&amp;rft.spage=239&amp;rft.epage=248&amp;rft.issn=1699-5848&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[20]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">A. Maniakas <i>et al.</i>, “Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019,” <i>JAMA Oncology</i>, vol. 6, no. 9, pp. 1397–1404, Sep. 2020, doi: <a href="https://doi.org/10.1001/jamaoncol.2020.3362">10.1001/jamaoncol.2020.3362</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1001%2Fjamaoncol.2020.3362&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Evaluation%20of%20Overall%20Survival%20in%20Patients%20With%20Anaplastic%20Thyroid%20Carcinoma%2C%202000-2019&amp;rft.jtitle=JAMA%20Oncology&amp;rft.stitle=JAMA%20Oncology&amp;rft.volume=6&amp;rft.issue=9&amp;rft.aufirst=Anastasios&amp;rft.aulast=Maniakas&amp;rft.au=Anastasios%20Maniakas&amp;rft.au=Ramona%20Dadu&amp;rft.au=Naifa%20L.%20Busaidy&amp;rft.au=Jennifer%20R.%20Wang&amp;rft.au=Renata%20Ferrarotto&amp;rft.au=Charles%20Lu&amp;rft.au=Michelle%20D.%20Williams&amp;rft.au=G.%20Brandon%20Gunn&amp;rft.au=Marie-Claude%20Hofmann&amp;rft.au=Gilbert%20Cote&amp;rft.au=Jared%20Sperling&amp;rft.au=Neil%20D.%20Gross&amp;rft.au=Erich%20M.%20Sturgis&amp;rft.au=Ryan%20P.%20Goepfert&amp;rft.au=Stephen%20Y.%20Lai&amp;rft.au=Maria%20E.%20Cabanillas&amp;rft.au=Mark%20Zafereo&amp;rft.date=2020-09-01&amp;rft.pages=1397-1404&amp;rft.spage=1397&amp;rft.epage=1404&amp;rft.issn=2374-2437"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[21]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">B. Lin <i>et al.</i>, “The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis,” <i>Am J Transl Res</i>, vol. 11, no. 9, pp. 5888–5896, 2019.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Apmid%2F31632557&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The%20incidence%20and%20survival%20analysis%20for%20anaplastic%20thyroid%20cancer%3A%20a%20SEER%20database%20analysis&amp;rft.jtitle=American%20Journal%20of%20Translational%20Research&amp;rft.stitle=Am%20J%20Transl%20Res&amp;rft.volume=11&amp;rft.issue=9&amp;rft.aufirst=Bo&amp;rft.aulast=Lin&amp;rft.au=Bo%20Lin&amp;rft.au=Haiqing%20Ma&amp;rft.au=Maoguang%20Ma&amp;rft.au=Zhicheng%20Zhang&amp;rft.au=Zicheng%20Sun&amp;rft.au=I.-Yun%20Hsieh&amp;rft.au=Okose%20Okenwa&amp;rft.au=Haoyan%20Guan&amp;rft.au=Jie%20Li&amp;rft.au=Weiming%20Lv&amp;rft.date=2019&amp;rft.pages=5888-5896&amp;rft.spage=5888&amp;rft.epage=5896&amp;rft.issn=1943-8141&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[22]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">V. Subbiah <i>et al.</i>, “Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer,” <i>J Clin Oncol</i>, vol. 36, no. 1, pp. 7–13, Jan. 2018, doi: <a href="https://doi.org/10.1200/JCO.2017.73.6785">10.1200/JCO.2017.73.6785</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1200%2FJCO.2017.73.6785&amp;rft_id=info%3Apmid%2F29072975&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Dabrafenib%20and%20Trametinib%20Treatment%20in%20Patients%20With%20Locally%20Advanced%20or%20Metastatic%20BRAF%20V600-Mutant%20Anaplastic%20Thyroid%20Cancer&amp;rft.jtitle=Journal%20of%20Clinical%20Oncology%3A%20Official%20Journal%20of%20the%20American%20Society%20of%20Clinical%20Oncology&amp;rft.stitle=J%20Clin%20Oncol&amp;rft.volume=36&amp;rft.issue=1&amp;rft.aufirst=Vivek&amp;rft.aulast=Subbiah&amp;rft.au=Vivek%20Subbiah&amp;rft.au=Robert%20J.%20Kreitman&amp;rft.au=Zev%20A.%20Wainberg&amp;rft.au=Jae%20Yong%20Cho&amp;rft.au=Jan%20H.%20M.%20Schellens&amp;rft.au=Jean%20Charles%20Soria&amp;rft.au=Patrick%20Y.%20Wen&amp;rft.au=Christoph%20Zielinski&amp;rft.au=Maria%20E.%20Cabanillas&amp;rft.au=Gladys%20Urbanowitz&amp;rft.au=Bijoyesh%20Mookerjee&amp;rft.au=Dazhe%20Wang&amp;rft.au=Fatima%20Rangwala&amp;rft.au=Bhumsuk%20Keam&amp;rft.date=2018-01-01&amp;rft.pages=7-13&amp;rft.spage=7&amp;rft.epage=13&amp;rft.issn=1527-7755&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[23]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">R. A. Ghossein, N. Katabi, and J. A. Fagin, “Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression,” <i>J Clin Endocrinol Metab</i>, vol. 98, no. 8, pp. E1414-1421, Aug. 2013, doi: <a href="https://doi.org/10.1210/jc.2013-1408">10.1210/jc.2013-1408</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1210%2Fjc.2013-1408&amp;rft_id=info%3Apmid%2F23775351&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Immunohistochemical%20detection%20of%20mutated%20BRAF%20V600E%20supports%20the%20clonal%20origin%20of%20BRAF-induced%20thyroid%20cancers%20along%20the%20spectrum%20of%20disease%20progression&amp;rft.jtitle=The%20Journal%20of%20Clinical%20Endocrinology%20and%20Metabolism&amp;rft.stitle=J%20Clin%20Endocrinol%20Metab&amp;rft.volume=98&amp;rft.issue=8&amp;rft.aufirst=Ronald%20A.&amp;rft.aulast=Ghossein&amp;rft.au=Ronald%20A.%20Ghossein&amp;rft.au=Nora%20Katabi&amp;rft.au=James%20A.%20Fagin&amp;rft.date=2013-08&amp;rft.pages=E1414-1421&amp;rft.spage=E1414&amp;rft.epage=1421&amp;rft.issn=1945-7197&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[24]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">C. G. Thomas and J. A. Buckwalter, “Cancer of the thyroid,” <i>Adv Surg</i>, vol. 10, pp. 245–285, 1976.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Apmid%2F790920&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cancer%20of%20the%20thyroid&amp;rft.jtitle=Advances%20in%20Surgery&amp;rft.stitle=Adv%20Surg&amp;rft.volume=10&amp;rft.aufirst=C.%20G.&amp;rft.aulast=Thomas&amp;rft.au=C.%20G.%20Thomas&amp;rft.au=J.%20A.%20Buckwalter&amp;rft.date=1976&amp;rft.pages=245-285&amp;rft.spage=245&amp;rft.epage=285&amp;rft.issn=0065-3411&amp;rft.language=eng"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[25]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">R. C. Smallridge and J. A. Copland, “Anaplastic thyroid carcinoma: pathogenesis and emerging therapies,” <i>Clin Oncol (R Coll Radiol)</i>, vol. 22, no. 6, pp. 486–497, Aug. 2010, doi: <a href="https://doi.org/10.1016/j.clon.2010.03.013">10.1016/j.clon.2010.03.013</a>.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1016%2Fj.clon.2010.03.013&amp;rft_id=info%3Apmid%2F20418080&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Anaplastic%20thyroid%20carcinoma%3A%20pathogenesis%20and%20emerging%20therapies&amp;rft.jtitle=Clinical%20Oncology%20(Royal%20College%20of%20Radiologists%20(Great%20Britain))&amp;rft.stitle=Clin%20Oncol%20(R%20Coll%20Radiol)&amp;rft.volume=22&amp;rft.issue=6&amp;rft.aufirst=R.%20C.&amp;rft.aulast=Smallridge&amp;rft.au=R.%20C.%20Smallridge&amp;rft.au=J.%20A.%20Copland&amp;rft.date=2010-08&amp;rft.pages=486-497&amp;rft.spage=486&amp;rft.epage=497&amp;rft.issn=1433-2981&amp;rft.language=eng"></span>
</div>
</body>
</html>
